Phase 1 study of MDM2 antagonist ASTX295 in patients with solid tumors with wild-type TP53

被引：1
|
作者：
Dumbrava, Ecaterina E.
Iwamoto, Fabio M.
Agulnik, Mark
Milhem, Mohammed
Tolcher, Anthony W.
Chugh, Rashmi
Demeure, Michael J.
Mita, Alain
Demel, Kurt
Diamond, Mark
Mirakhur, Beloo
Wilson, Laksmi
Oganesian, Aram
Chan, Danna
Keer, Harold N.
Taylor, Jason
Sims, Martin J.
Biondo, Andrea
Jueliger, Simone
Spira, Alexander
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2024-CT066
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT066
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53
    Saleh, Mansoor N.
    Patel, Manish R.
    Bauer, Todd M.
    Goel, Sanjay
    Falchook, Gerald S.
    Shapiro, Geoffrey, I
    Chung, Ki Y.
    Infante, Jeffrey R.
    Conry, Robert M.
    Rabinowits, Guilherme
    Hong, David S.
    Wang, Judy S.
    Steidl, Ulrich
    Naik, Gurudatta
    Guerlavais, Vincent
    Vukovic, Vojislav
    Annis, D. Allen
    Aivado, Manuel
    Meric-Bernstam, Funda
    [J]. CLINICAL CANCER RESEARCH, 2021, 27 (19) : 5236 - 5247
  • [2] TP53 wild-type/PPM1D mutant diffuse intrinsic pontine gliomas are sensitive to a MDM2 antagonist
    Cheng Xu
    Heng Liu
    Christopher J. Pirozzi
    Lee H. Chen
    Paula K. Greer
    Bill H. Diplas
    Liwei Zhang
    Matthew S. Waitkus
    Yiping He
    Hai Yan
    [J]. Acta Neuropathologica Communications, 9
  • [3] TP53 wild-type/PPM1D mutant diffuse intrinsic pontine gliomas are sensitive to a MDM2 antagonist
    Xu, Cheng
    Liu, Heng
    Pirozzi, Christopher J.
    Chen, Lee H.
    Greer, Paula K.
    Diplas, Bill H.
    Zhang, Liwei
    Waitkus, Matthew S.
    He, Yiping
    Yan, Hai
    [J]. ACTA NEUROPATHOLOGICA COMMUNICATIONS, 2021, 9 (01)
  • [4] Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma
    W. Larry Gluck
    Mrinal M. Gounder
    Richard Frank
    Ferry Eskens
    Jean Yves Blay
    Philippe A. Cassier
    Jean-Charles Soria
    Sant Chawla
    Vincent de Weger
    Andrew J. Wagner
    David Siegel
    Filip De Vos
    Erik Rasmussen
    Haby A. Henary
    [J]. Investigational New Drugs, 2020, 38 : 831 - 843
  • [5] Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma
    Gluck, W. Larry
    Gounder, Mrinal M.
    Frank, Richard
    Eskens, Ferry
    Blay, Jean Yves
    Cassier, Philippe A.
    Soria, Jean-Charles
    Chawla, Sant
    de Weger, Vincent
    Wagner, Andrew J.
    Siegel, David
    De Vos, Filip
    Rasmussen, Erik
    Henary, Haby A.
    [J]. INVESTIGATIONAL NEW DRUGS, 2020, 38 (03) : 831 - 843
  • [6] Discovery of ASTX295, a potent, next-generation small molecule antagonist of MDM2 with differentiated pharmacokinetic profile
    Ahn, Maria
    Bevan, Luke
    Buck, Ildiko
    Cano, Celine
    Castro, Juan
    Cons, Ben
    Endicott, Jane
    Fazal, Lynsey
    Ferrari, Nicola
    Hardcastle, Ian
    Hearn, Keisha
    Holvey, Rhian
    Howard, Steven
    Johnson, Chris
    Jennings, Claire
    Kucia-Tran, Justyna
    Kyle, Suzanne
    Lunec, John
    Lyons, John
    Miller, Duncan
    Rees, David
    Noble, Martin
    Newell, David R.
    Reeks, Judith
    Saini, Harpreet
    Denis, Jeffrey St.
    Tamanini, Emiliano
    Thomas, Huw
    Thompson, Neil
    Vinkovic, Mladen
    Ward, George
    Wallis, Nicola
    Walton, Hugh
    Wedge, Stephen
    Williams, Pamela
    Willmore, Elaine
    Wilshire, Nicola
    Zhao, Yan
    Chessari, Gianni
    [J]. CANCER RESEARCH, 2024, 84 (06)
  • [7] Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2-Amplified and TP53 Wild-type Glioblastomas
    Verreault, Maite
    Schmitt, Charlotte
    Goldwirt, Lauriane
    Pelton, Kristine
    Haidar, Samer
    Levasseur, Camille
    Guehennec, Jeremy
    Knoff, David
    Labussiere, Marianne
    Marie, Yannick
    Ligon, Azra H.
    Mokhtari, Karima
    Khe Hoang-Xuan
    Sanson, Marc
    Alexander, Brian M.
    Wen, Patrick Y.
    Delattre, Jean-Yves
    Ligon, Keith L.
    Idbaih, Ahmed
    [J]. CLINICAL CANCER RESEARCH, 2016, 22 (05) : 1185 - 1196
  • [8] A phase 2 study of the MDM2 inhibitor milademetan in patients with TP53-wild type and MDM2-amplified advanced or metastatic solid tumors (MANTRA-2)
    Dumbrava, Ecaterina Elena
    Hanna, Glenn J.
    Cote, Gregory Michael
    Stinchcombe, Tom
    Johnson, Melissa Lynne
    Chen, Christopher
    Devarakonda, Siddhartha
    Shah, Naisargee
    Xu, Feng
    Doebele, Robert Charles
    Gounder, Mrinal M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [9] Phase I Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53 (vol 27, pg 5236, 2021)
    Saleh, Mansoor N.
    Patel, Manish R.
    Bauer, Todd M.
    Goel, Sanjay
    Falchook, Gerald S.
    Shapiro, Geoffrey I.
    Chung, Ki Y.
    Infante, Jeffrey R.
    Conry, Robert M.
    Rabinowits, Guilherme
    Hong, David S.
    Wang, Judy S.
    Steidl, Ulrich
    Walensky, Loren D.
    Naik, Gurudatta
    Guerlavais, Vincent
    Vukovic, Vojislav
    Annis, D. Allen
    Aivado, Manuel
    Meric-Bernstam, Funda
    [J]. CLINICAL CANCER RESEARCH, 2022, 28 (02) : 429 - 429
  • [10] RNA Sequencing Reveals Candidate Genes and Pathways Associated with Resistance to MDM2 Antagonist Idasanutlin in TP53 Wild-Type Chronic Lymphocytic Leukemia
    Aptullahoglu, Erhan
    Nakjang, Sirintra
    Wallis, Jonathan P.
    Marr, Helen
    Marshall, Scott
    Willmore, Elaine
    Lunec, John
    [J]. BIOMEDICINES, 2024, 12 (07)
12345